Table 2

Demographic and clinical characteristics of overall patients with pancreatic cancer in population-based registries*

ParameterUSAThe NetherlandsBelgiumNorwayDenmarkSloveniaEstonia
Incidence period2004–20132003–20142004–20132003–20142011–20162003–20132009–2014
n96 57322 47812 1457686408633221410
Sex, female48 317 (50.0)11 184 (49.8)5902 (48.6)3973 (51.7)2149 (52.6)1691 (50.9)665 (47.2)
Age (year)70±1270±1170±1172±1270±1070±1171±11
Age group
 <60 years19 676 (20.4)4199 (18.7)2207 (18.2)1155 (15.0)619 (15.2)625 (18.8)230 (16.3)
 60–69 years24 334 (25.2)6425 (28.6)3176 (26.2)1956 (25.5)1319 (32.3)810 (24.4)370 (26.2)
 70–79 years27 073 (28.0)7320 (32.6)4192 (34.5)2268 (29.5)1490 (36.5)1120 (33.7)493 (35.0)
 ≥80 years25 490 (26.4)4534 (20.2)2570 (21.2)2307 (30.0)658 (16.1)767 (23.1)317 (22.5)
Tumour location†
 Pancreas head46 734 (67.8)13 997 (72.3)4087 (68.9)2673 (72.9)2134 (68.8)1445 (74.7)754 (68.3)
 Pancreas body10 769 (15.6)2288 (11.8)815 (13.7)492 (13.4)508 (16.3)226 (11.7)213 (19.3)
 Pancreas tail11 453 (16.6)3079 (15.9)1034 (17.4)490 (13.4)462 (14.9)264 (13.6)137 (12.4)
 Other27 617 (28.6)3114 (13.8)6209 (51.1)4021 (52.4)982 (24.0)1387 (41.8)306 (21.7)
cTNM stage‡
 I–II31 313 (36.2)5184 (27.2)2123 (29.2)1545 (25.0)801 (26.7)457 (18.8)283 (25.2)
 III8033 (9.3)1937 (10.1)936 (12.9)395 (6.4)419 (13.9)205 (8.4)118 (10.5)
 IV47 120 (54.5)11 993 (62.7)4217 (58.0)4238 (68.6)1785 (59.4)1773 (72.8)721 (64.3)
Resection15 628 (16.2)2945 (13.1)2630 (21.7)1005 (13.1)690 (16.9)602 (18.1)183 (13.0)
ChemotherapyNA5061 (22.5)6958 (57.3)1567 (20.4)2164 (53.0)581 (17.5)211 (15.0)
Radiotherapy5282 (5.5)510 (2.3)836 (6.9)319 (4.2)149 (3.7)64 (1.9)34 (2.4)
  • *Enumeration data are shown as count (percentage (%)) and measurement data as mean±SD. Records are complete otherwise specified below.

  • †The percentages of pancreas head, body and tail are the proportions compared with the total tumour cases of pancreas head, body and tail; other: pancreas duct, overlapping lesion, NOS and other specified parts.

  • ‡Unknown cTNM (clinical TNM) stage: USA, 10 107 (10.5%); the Netherlands, 3364 (15.0%); Belgium, 4869 (40.1%); Norway, 1508 (19.6%); Denmark, 1081 (26.5%); Slovenia, 887 (26.5%) and Estonia, 288 (20.4%). For USA, Norway and Estonia, the stage is a combination of clinical and pathological ones. The summary stage was used to help retrieve missing TNM stages.

  • NA, not available; NOS, not otherwise specified; TNM, tumour, node, metastasis.